Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.
The genetic cause of antiphospholipid syndrome is unknown. This condition results from the presence of three abnormal immune proteins (antibodies) in the blood. The antibodies that cause antiphospholipid syndrome are called lupus anticoagulant, anticardiolipin, and anti-B2 glycoprotein I. These antibodies are referred to as antiphospholipid antibodies. People with this condition can test positive for one, two, or all three antiphospholipid antibodies in their blood. Antibodies normally attach (bind) to specific foreign particles and germs, marking them for destruction, but the antibodies in antiphospholipid syndrome attack normal human proteins. When these antibodies attach to proteins, the proteins change shape and attach to other molecules and receptors on the surface of cells. Attaching to cells, particularly immune cells, turns on (activates) the blood clotting pathway and other immune responses.
Antiphospholipid syndrome is estimated to affect 1 in 2,000 people. This condition may be responsible for up to one percent of all thromboses. It is estimated that 20 percent of individuals younger than age 50 who have a stroke have antiphospholipid syndrome. Ten to 15 percent of people with systemic lupus erythematosus have antiphospholipid syndrome. Similarly, 10 to 15 percent of women with recurrent miscarriages likely have this condition. Approximately 70 percent of individuals diagnosed with antiphospholipid syndrome are female.
Most cases of antiphospholipid syndrome are sporadic, which means they occur in people with no history of the disorder in their family. Rarely, the condition has been reported to run in families; however, it does not have a clear pattern of inheritance. Multiple genetic and environmental factors likely play a part in determining the risk of developing antiphospholipid syndrome.
Thomas Ortel is a Hematologist in Durham, North Carolina. Ortel has been practicing medicine for over 38 years and is rated as an Elite expert by MediFind in the treatment of Antiphospholipid Syndrome. He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Antiphospholipid Syndrome, Mesenteric Venous Thrombosis, Knee Replacement, and Hip Replacement. Ortel is currently accepting new patients.
Stephane Zuily practices in Nancy, France. Zuily is rated as an Elite expert by MediFind in the treatment of Antiphospholipid Syndrome. She is also highly rated in 8 other conditions, according to our data. Her top areas of expertise are Antiphospholipid Syndrome, Factor V Leiden Thrombophilia, Livedo Reticularis, and Systemic Lupus Erythematosus (SLE).
Savino Sciascia practices in Turin, Italy. Sciascia is rated as an Elite expert by MediFind in the treatment of Antiphospholipid Syndrome. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Antiphospholipid Syndrome, Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Glomerulonephritis.
Summary: The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0,...
Summary: The aim of this study was to observe the clinical efficacy and safety of rituximab (RTX) combination with telitacicept (TA) in patients of systemic lupus erythematosus secondary antiphospholipid syndrome (APS).
Published Date: July 11, 2022Published By: National Institutes of Health